Article info
PDFClinical and epidemiological research
Concise report
Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis
- Correspondence to Dr Shunsuke Mori, Department of Rheumatology, Clinical Research Center for Rheumatic Disease, NHO Kumamoto Saishunsou National Hospital, 2659 Suya, Kohshi, Kumamoto 861-1196, Japan; moris{at}saisyunsou1.hosp.go.jp
Citation
Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis
Publication history
- Received July 7, 2012
- Accepted July 26, 2012
- First published August 11, 2012.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online table 1
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode